Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians ...

NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...

ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the need for corticosteroid use in patients with noninfectious uveitis, according ...

The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion USA, announced today. It ...

SAN DIEGO, CA—Do tumor necrosis factor inhibitors (TNFi) improve HbA1c in patients with rheumatoid arthritis? The answer depends on the agent and on whether patients have diabetes mellitus, according ...

Despite the influx of adalimumab biosimilars entering the market in 2023, Humira remains on top. As of January 2024, both high and low concentrations of Humira, the originator adalimumab product, are ...

Biocon Biologics, a fully integrated global biosimilars company and subsidiary of India’s Biocon Ltd, announced that it has ...